Physician profile
Aaron Pinion
NPI 1255642294
$4,367.09
in general payments reported to CMS, 2019-2025
22 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $1,587 · 2023: $519 · 2024: $553 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.87 |
| Education | $194.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,230.68 | 2022-2024 | Xolair |
| Genzyme Corporation | $892.52 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $844.44 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $194.94 | 2025 | |
| Csl Behring | $193.86 | 2025 | Hizentra, Andembry |
| Amgen INC. | $165.68 | 2022-2025 | Tezspire |
| Lilly USA, LLC | $125.64 | 2023-2025 | Ebglyss, Mounjaro, Taltz |
| Abbvie INC. | $118.61 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $115.82 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.56 | 2022-2025 | Hyqvia, Eohilia |
| Kerecis Limited | $71.38 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Graftguide |
| Regeneron Healthcare Solutions, INC. | $70.66 | 2023-2024 | Dupixent |
| Ionis Pharmaceuticals, INC. | $53.56 | 2025 | Dawnzera |
| Pfizer INC. | $35.53 | 2024-2025 | |
| Pharming Healthcare, INC. | $32.56 | 2025 | Ruconest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $30.34 | 2025 | Ayvakit |
| Ultragenyx Pharmaceutical INC. | $18.07 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2022 | |
| Horizon Therapeutics Plc | $14.27 | 2023 | Actimmune |
| Sanofi Pasteur INC. | $13.92 | 2024 | |
| Aimmune Therapeutics, INC. | $13.63 | 2021 | |
| Mdd US Operations, LLC | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Pinion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.